On November 2, 2001, the country watched and listened with fascination when Robert Tools, the recipient of the first AbioCor artificial heart, let Stone Phillips of NBC's "Dateline" broadcast its beat on national TV.
This was the first time the public had seen an artificial heart recipient able to stand and walk on his own. Still, the device did more than get Tools back on his feet. It focused the national spotlight on Kentucky, where the device was implanted.
Sadly, Tools died 151 days after his amazing surgery, but the next critically ill heart patient, Tom Christerson, lived for almost a year and a half after receiving the AbioCor. Today the pioneering spirit these patients and their doctors displayed is still thriving in the Bluegrass State.
A great example is the Cardiovascular Innovation Institute, a new research facility created through a partnership of the University of Louisville (U of L) and Jewish Hospital, also located in Louisville.
This $50 million institute, which also receives financial support from the Kentucky Economic Development Cabinet's Department of Commercialization and Innovation (DCI), the federal government, and private sources, continues the commonwealth's tradition of introducing artificial heart devices that started back in the 1980s. It focuses on developing more effective and less intrusive devices for patients with advanced heart disease.
The Advanced State of Biotechnology in Kentucky
Thanks to Kentucky's pioneering and progressive tax laws and proactive incentive programs, hundreds of life-science-related companies have already flocked to the Bluegrass State.
Other states often claim to be friendly to business, but Kentucky consistently backs it up. For instance, Kentucky has consistently ranked among the most competitive states when it comes to assisting businesses looking to expand existing facilities or develop new ones. You will also find Kentucky and some of its leading biotech companies and R&D institutions at prestigious industry showcases, such as the June 2008 BIO International
Convention in San Diego
One of the first large biotechnology companies to settle in Kentucky was Martek Biosciences. A spinoff from defense and aerospace giant Martin Marietta, Martek discovered how to extract fatty acids - essential nutrients for the human body - from marine algae. Two of Martek's fatty acid products (originally developed for America's space program) are now added to 80 percent of all baby formulas sold.
When those children are old enough to drink real milk, Alltech, a global biotech headquartered in Kentucky, will have made it safer and cheaper to drink. The company uses its expertise in fermentation and enzymes to improve the quality of animal feed, while lowering its costs. Today, Alltech has manufacturing facilities in 14 countries and annual revenues of more than $400 million.
In October 2007, Alltech learned that it would receive funding from the commonwealth of Kentucky to create a rural community biorefinery in Springfield, Kentucky. This is the first such model in North America that integrates feed, food and fuel production. In addition to ethanol production, the biorefinery will provide value added products through secondary fermentation.
Another Kentucky biotech that concentrates on improving the health of animals is Equine Biodiagnostics Inc., located on the 735-acre University of Kentucky (UK) Coldstream Research Campus. The company assists over 4,000 veterinary practitioners worldwide in accurately diagnosing equine infectious diseases through its specialized molecular-testing capabilities.
Pharmaceuticals and Natural Products Research
Kentucky is playing an ever-increasing role in the development of oral and injectable medicines for humans. Since its start in 1986, the Center for Pharmaceutical Science and Technology (CPST), located on the main campus of UK in Lexington, has developed and manufactured drugs for over 200 research projects utilizing current best manufacturing practices. Many of the projects that the center has been involved in have led directly to clinical trials.
Recently, the CPST was spun off as a private company, called Coldstream Laboratories, and opened an advanced pharmaceutical manufacturing factory at UK's Coldstream Research Campus. The new $17 million Coldstream Laboratories, which opened in July 2007, offers full-service pharmaceutical R&D support and sterile drug manufacturing for clinical trials and some niche commercial products.
The development of natural products and supplements is also being enhanced in Kentucky. September 2006 witnessed the grand opening of Kentucky BioProcessing, LLC in Owensboro. The company, which extracts purified proteins and other value-added products from plants and organic materials, was partially funded by a $3.6 million loan by the Kentucky Agriculture Finance Corporation. Kentucky BioProcessing will pave the way to producing more natural products and create more opportunities for Kentucky farmers.
Kentucky BioProcessing is a contract bioprocessor with state-of-the-art facilities, experienced personnel, and intellectual property that provides customers with an unequaled quality and range of bioprocessing services. The company works with customers on a confidential basis to extract purified proteins and other value added products from plants and other organic materials.